Autopsy report · NCT01319760

MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction

“Change in business priority”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 11 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 6 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Abiomed Inc.

Sponsor type

Industry

Conditions

ST-elevation Myocardial Infarction

Interventions

Impella 2.5 support; Standard of care (Control)

Participants

5

Trials that died the same way

• A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures
  “Change in business priorities.” (83% match in meaning)
• Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
  “Change in company priorities” (80% match in meaning)
• 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
  “Business priorities” (74% match in meaning)
• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (60% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.